Abcellera Biologics vs Xilio Therapeutics
Abcellera Biologics is the larger business, with $75.1m of revenue in fiscal 2025 against $43.8m for Xilio Therapeutics (1.7 times as much). Xilio Therapeutics grew faster (589.9% against 160.6%). Xilio Therapeutics kept more of each dollar of sales as profit: a net margin of -80.1% against -194.9%. Abcellera Biologics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Abcellera BiologicsABCL, 2025 | Xilio TherapeuticsXLO, 2025 |
|---|---|---|
| Revenue | $75.1m | $43.8m |
| Revenue growth | 160.6% | 589.9% |
| Net income | −$146m | −$35.0m |
| Operating margin | -289.0% | -95.9% |
| Net margin | -194.9% | -80.1% |
| Return on equity | -14.5% | -132.5% |
| Free cash flow | −$174m | −$5.5m |
| Cash | $129m | $138m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 562 | 76 |
| Market value | $3.71bn | $56.6m |
| Price vs our value range | — | — |
| Moat score | 17 (Weak) | — |
| Insider trades, 12 months | 9 buys, 0 sales | 1 buys, 2 sales |